The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.

In the short term, biosimilar market growth will be driven by drug classes including erythropoietin, filgrastim, human growth hormone (hGH) and insulin. ‘The Top 10 Biosimilars Players: Positioning, performance and SWOT analyses' is a report published by Business Insights that examines the competitive landscape of the global biosimilars industry. The latest key issues and evolving business models in the biosimilars market are identified and the leading companies in this sector are profiled in detail. This report examines the portfolio sales performances, pipelines and growth strategies of each of the top 10 biosimilars companies. The opportunities and threats facing each of these leading players are also assessed. This report also examines the size, growth and major trends of the global biosimilars industry, in addition to providing to an assessment of leading biosimilars companies outside of the top 10.

Read more...

• Emerging Biosimilars Landscape (21/01/2010)
• Biosimilars: Key developments in the regulatory environment (08/12/2009)
• Biosimilars expansion in the USA (14/07/2009)

• Emerging Clinical Trial Locations (21/01/2010)
• Key Trends In Drug-diagnostic Co-development (21/01/2010)

• New Approaches to Pharma R&D (08/12/2009)
• Generic Benchmarking (14/07/2009)
• Biosimilars (14/07/2009)
• Early Stage Drug Safety Strategies and Risk Management (14/07/2009)
• Pharmaceutical Distribution in Bosnia and Herzegovina (09/07/2009)
• Valuing Pharmaceutical Innovation (14/10/2008)
• Rx-to-OTC Strategies (10/10/2008)
• Optimizing Brand Lifecycle Management (09/10/2008)
• Drug Repositioning Strategies (10/06/2008)

---